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Background: Gender, smoking history, adenocarcinoma histology,
performance status, and East Asian ethnicity were predictive factors
of gefitinib response in previous analysis. However, these factors
tend to be correlated with each other; it is not clear whether gender,
smoking history, and adenocarcinoma histology were all indepen-
dent predictors for response in East Asian populations.
Methods: Tumor response, survival and predictive factors of ge-
fitinib response of advanced non-small cell lung cancer patients
treated between May of 2002 and November of 2004 were collected
retrospectively from three medical centers in Taiwan. Univariate and
multivariate logistic regression models were used to test potential
predictive factors associated with response to gefitinib. Overall
survivals between groups with different predictive factors were
compared by log-rank tests. Multivariate analyses were performed to
identify factors that independently predict for survival.
Results: A total of 428 patients were analyzed. The median fol-
low-up duration for living patients was 19.5 months (range, 10.2–
39.9). Objective tumor response was observed in 114 patients
(26.6%, 95% confidence interval [CI]: 22.4%–30.8%) and disease
stabilization in 129 patients (30.2%). Response rate was statistically
significant higher in adenocarcinoma, good performance status, and
chemonaive patients in multivariate analysis. The median survival
was 7.4 months (95% CI: 5.8–9.0) and 1-year survival was 34.3%
(95% CI: 29.0%–38.0%). Significant independent predictive factors
associated with longer survival in multivariate analysis were good
performance status (p  0.001) and responsiveness to gefitinib (p 
0.001). In 286 chemotherapy-treated patients, the response rate was
22.7%. Median and 1-year survival was 7.9 months and 36.7%,
respectively. Good performance status was predictive of tumor
response (p  0.001) and better survival (p  0.001) in multivariate
analysis. Response to gefitinib was predictive of better survival (p
0.001).
Conclusions: Gender and smoking status were not, but good per-
formance status (PS), no previous chemotherapy, and adenocarci-
noma histology were independent predictive factors in multivariate
analysis for gefitinib response in Taiwanese advanced non-small cell
lung cancer population. In patients previously treated with chemo-
therapy, only good PS was an independent predictor for tumor
response in multivariate analysis.
Key Words: Gefitinib, Non-small cell lung cancer, Predictive fac-
tor, Chemonaive, Performance status.
(J Thorac Oncol. 2006;1: 520–525)
Lung cancer is the leading cause of cancer deaths world-wide. The prognosis of lung cancer is poor despite the
advances in clinical research for decades, with a 5-year
survival rate for all stages 15%.1 The prognosis was poor
for chemotherapy-refractory non-small cell lung cancer
(NSCLC) patients under best supportive care, with a median
survival time of only 16 weeks.2 A therapeutic blockade of
the epidermal growth factor receptor (EGFR) signaling path-
ways was developed to treat human cancers that are refrac-
tory to conventional therapies. Gefitinib (Iressa, ZD1839;
AstraZeneca, Wilmington, DE) effectively inhibits the li-
gand-induced EGFR tyrosine kinase activity in vitro.
Gefitinib has shown modest activity in advanced
NSCLC who have progressive disease after chemotherapy in
two phase II clinical trials.3,4 Gender, adenocarcinoma his-
tology, and PS were predictive factors for gefitinib response
in these two studies. A placebo-controlled phase III study
(Iressa Survival Evaluation in Lung Cancer [ISEL]) failed to
demonstrate survival advantage for advanced NSCLC pa-
tients who were refractory to chemotherapy. However, the
same study has shown that Asian ethnic origin and smok-
ing were two independent factors to predict better survival
after gefitinib treatment.5 The results of several studies in
East Asian population were in line with the findings
in ISEL study demonstrating the high activity of gefitinib
in this population.6–14
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As gefitinib is predominantly effective in East Asian
populations, it is important to determine the factors predictive
of response and better survival among East Asian patients.
Several retrospective studies were performed in this regard.
However, different independent predictive factors were found
in these studies.9,11,14 Small sample size and preselected
patient populations were limiting factors for these analyses.
In this study, we evaluated the antitumor activity of gefitinib
in patients with advanced NSCLC from three Taiwan medical
centers. Because most patients were treated before people
learned about the current known predictive factors, these
patients were relatively unselected.
PATIENTS AND METHODS
Patient and Gefitinib Treatment
Advanced NSCLC patients who received gefitinib 250
mg/day with assessable disease between May of 2002 and
November of 2004 were identified and included in this
retrospective analysis. The patients were from three tertiary
referral centers at Taiwan including Taichung Veterans Gen-
eral Hospital, Taipei Veterans General Hospital, and National
Taiwan University Hospital. Medical charts, imaging reports,
and films were retrospectively reviewed in each center. To be
included in this analysis, the following criteria had to be met:
the diagnosis of NSCLC confirmed histologically or cytolog-
ically; advanced stage IIIB or stage IV disease, not curable
with surgery or radiotherapy; and recurrent or refractory
disease after chemotherapy or refusal of chemotherapy. The
patients had to have at least one measurable or assessable
lesion. Clinical data collected included patient’s age, gender,
Eastern Cooperative Oncology Group (ECOG) PS, tumor
histology, stage, smoking status (nonsmoking defined as
patients had never smoked), previous metastatic sites and
treatment, date of diagnosis, treatment, progression, death or
last follow-up, best response to gefitinib treatment, side
effects of gefitinib treatment, and any chemotherapy after
failing gefitinib treatment.
Response and Toxicity Assessment
Baseline assessments were usually performed within 2
weeks before treatment. After the start of treatment, chest
radiography assessments were performed every 2 to 3 weeks
and as needed and then every 4 weeks after the third month
to evaluate response and detect pulmonary toxicity. Chest
computed tomography scan (including liver and adrenal
glands) was performed every 2 to 3 months as routine clinical
practice and as needed to confirm the response or evaluate the
acute interstitial lung disease. Lesions were reviewed and
evaluated for response according to standard criteria15 as
complete response (CR), partial response (PR), stable disease
(SD), or progressive disease (PD). Data for patients who were
alive were censored as of the date of the last follow-up visit.
Survival time was calculated from the starting date of ge-
fitinib to the date of death. Adverse events and toxicity during
treatment were coded according to National Cancer Institute
expanded common toxicity criteria (CTC), version 2.0.
Statistical Methods
Overall survival was estimated by the Kaplan-Meier
method. The significance of the difference between groups
was compared by log-rank test. Multivariate analyses were
performed by Cox proportional hazards model to further
explore observed differences and to identify baseline factors
including response status (CR, PR, SD, or PD), ECOG PS (0,
1 versus 2, 3, 4), histology type (adenocarcinoma vs. non-
adenocarcinoma), gender, previous chemotherapy, and smok-
ing status (never smoker versus ever smoker). The response
rates were compared between chemonaive patients and pa-
tients who previously received chemotherapy using Fisher’s
exact test. Univariate and multivariate logistic regression
models were used to further explore observed differences and
to identify baseline factors that may independently predict for
tumor response. Two-sided p values of 0.05 were consid-
ered significant. All analyses were performed using SPSS for
Windows, version 11.5 (SPSS Inc., Chicago, IL).
RESULTS
Patient Characteristics
Four hundred fifty-one patients were surveyed, and 23
patients were excluded because of no measurable or assess-
able lesions or early stages of disease. A total of 428 patients
(237 male, 191 female) were included in this analysis. Some
of the patients in this cohort were analyzed and reported
previously.13,16,17 The baseline demographic factors are
shown in Table 1. One hundred forty-two patients (33.2%)
received gefitinib as first-line treatment (Table 2). There were
more male patients, nonadenocarcinoma histology, and
smoking patients in the chemonaive patients compared to
patients who had previously received chemotherapy. The
main reasons for chemonaive patients to select gefitinib as
first-line treatment were poor PS, comorbidity, or refusal of
chemotherapy. One hundred eleven patients (25.9%) had
radiographically documented brain metastasis and had re-
ceived radiotherapy to the brain before they started gefitinib
treatment. Only a limited number of patients had brain irra-
diation and gefitinib treatment at the same time. In these
patients, response to brain radiotherapy was not considered a
gefitinib response in this analysis. Some of the patients had
previous palliative lung tumor irradiation. However, none of
the patients had palliative lung tumor irradiation and gefitinib
treatment at the same time.
Efficacy
Two patients (0.4%) had a complete response, 112
patients (26.2%) had a partial response, and 129 patients
(30.2%) had stable disease. The overall response rate was
26.6% (95% confidence interval: 22.4%–30.8%). Disease
control rate was 56.8% (95% confidence interval: 52.1%–
61.5%). In univariate analysis, female patients, good PS
(ECOG 0 or 1), chemonaive status, adenocarcinoma histol-
ogy, and never smoker were associated with responsiveness
to gefitinib. However, in multivariate analysis, gender and
smoking status were not independent predictors of response
(Table 3). At the time of analysis, only 60 patients were still
alive. The median follow-up duration for all living patients
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was 19.5 months (range, 10.2–39.9). The median overall sur-
vival (OS) for the whole population was 7.4 months (95%
confidence interval: 5.8–9.0) and the 1-year survival rate was
34.3% (95% confidence interval: 29.0%–38.0%). The associa-
tions between potential predictive factors for OS are shown in
Table 4. Only good PS and tumor response were associated with
significantly improved OS in multivariate analysis.
The effectiveness of gefitinib in 286 chemotherapy-
treated patients was analyzed and shown in Table 5 and 6.
The only independent predictive factor for response was PS
before treatment. Only good PS and responsiveness to ge-
fitinib may be predictive of better survival in this analysis.
The median OS rates were similar for both chemonaive and
patients who previously received chemotherapy. The median
OS and 1-year survival rate of 286 chemotherapy-treated
patients were 7.9 months and 36.7%, respectively. The poor
OS of the 142 chemonaive patients may be due the fact that
many of those patients had a poor PS at the time of treatment.
Median OS for patients who responded, those who had stable
disease, and those with progressive disease were 15.7, 8.7,
and 1.9 months, respectively (p  0.0001).
Safety and Tolerability
Most drug-related adverse events were mild (CTC
grade 1 or 2) (Table 7) and most events were reversible. Of
the patients, 12.4% experienced grade 3/4 toxicities. Paro-
nychia of various severities was found in 14.3% of patients.
Twelve episodes (2.8%) of acute interstitial pneumonia were
noted in these patients. Four patients died of this complica-
tion. These patients had acute onset dyspnea, and the median
time of onset was 42 days after the use of gefitinib.
DISCUSSION
The response rate in this series of patients in Taiwan is
similar to what has been reported in other East Asian popu-
lations. The higher response rate in our patients is similar to
that of other studies in Asian countries and has been consis-
tently observed in our clinical practice. In East Asian studies,
the average response rate for gefitinib in chemotherapy-
treated patients with advanced NSCLC was 22.7% (665/2931
patients) (range, 20.2%–38.8%)3,6–13 compared to 7.5% re-
sponse rate in white patients (118/1575 patients) (range,
0%–15%).4,18–33 Gefitinib thus played a much more impor-
tant role in the treatment of NSCLC in East Asian countries
than in Western countries.
Because the effectiveness of gefitinib in advanced
NSCLC in East Asian countries is comparable to that of
combination chemotherapy, selecting the right patients to be
treated with gefitinib is of vital importance. Several retro-
spective studies from these regions had yielded different
predictive factors after multivariant analysis.3,9,11,14 The
power of these analyses was limited to the small sample size
of the patients. Preselection of the treated populations with
good predictive factors may further lower the power to detect
differences of response. In our retrospective analysis, many
of these patients were treated before the predictive factors
were revealed. The proportions of male gender, nonadeno-
carcinoma histology, and smoking history were about the
same. In addition, high number of patients increased our
confidence in determining the right predictive factors to select
patients. In our study, 20% of male or smoking patients
responded to gefitinib. These two factors were not indepen-
dent factors for predicting response. Thus, it is reasonable to
use histology as a sole selecting factor in our population. In
patients previously treated with chemotherapy, tumor histol-
ogy was not an independent factor for predicting response or
TABLE 1. Demographic Data of 428 Patients
Variables No. of patients (%)
Age, y
Median (range) 63 (20–90)
Gender
Male 237 (55.4)
Female 191 (44.6)
Stage
IIIB 47 (11)
IV 381 (89)
Performance status
0 21 (4.9)
1 149 (34.8)
2 96 (22.4)
3 119 (27.8)
4 43 (10.0)
Previous chemotherapy regimens
0 142 (33.2)
1 130 (30.4)
2 82 (19.2)
3 52 (12.1)
4 17 (4.0)
4 5 (1.1)
Histology
Adenocarcinoma 319 (74.5)
Squamous cell carcinoma 68 (15.9)
Large-cell carcinoma 6 (1.4)
Others 35 (8.1)
Smoking history
Yes 215 (50.2)
No 213 (49.8)
TABLE 2. Comparison of Demographic Data between 142
Chemonaive and 286 Chemotherapy-Treated Patients
Chemonaive
No. (%)
Chemotherapy
treated No. (%) p
Gender 0.039
Male 89 (62.7) 148 (51.7)
Female 53 (37.3) 138 (48.3)
Performance status 0.208
0-1 50 (35.2) 120 (42.0)
2-4 92 (64.8) 166 (58.0)
Histology 0.032
Adenocarcinoma 97 (68.3) 222 (77.6)
Nonadenocarcinoma 45 (31.7) 64 (22.4)
Smoking history 0.031
Yes 82 (57.7) 133 (46.5)
No 60 (42.3) 153 (53.5)
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survival. Thus, in East Asian populations, we cannot exclude
patients from gefitinib treatment based on the presence of
only one or two of these predictive factors. Patients with a
history of smoking still had a reasonable chance to have a
response to gefitinib. However, our analysis was limited by
failure to quantify smoking history and separate patients into
heavy smokers and light smokers. Previous studies did show
a dose-response relationship between the amounts of previ-
ously smoked cigarettes to the response to gefitinib.
In this analysis, chemonaive patients had higher re-
sponse rate to gefitinib than chemotherapy-treated patients.
Other studies also suggested that gefitinib could be used as a
first-line treatment for patients with advanced NSCLC with
severe comorbidity, poor PS, or refusal of chemothera-
py.24,32,34 Lee et al.35 reported a response rate of 69% (25/36
patients) for gefitinib in never-smoking patients with ad-
vanced or metastatic lung adenocarcinoma. West et al.32
reported a higher gefitinib-induced response rate in chemona-
ive than chemotherapy-treated bronchioloalveolar cell carci-
noma patients. A plausible explanation for the higher re-
sponse rate in chemonaive patients is that chemotherapy may
alter EGFR expression in cancer cells, thereby reducing or
abrogating the effects of gefitinib. Another possibility is that
with a longer time after diagnosis, tumor cells will evolve
into a more heterogeneous and resistant phenotype and result
in resistance to gefitinib. However, in the Iressa Dose Eval-
uation in Advanced Lung Cancer (IDEAL)-2 trial in patients
who had previously undergone chemotherapy, there was a
trend for an increased response to gefitinib for patients
receiving more regimens previously. The response rate was
8% for patients receiving two, 10% for three, and 15% for
four or more previous regimens of chemotherapy.4 Although
the response rate was higher in chemonaive patients in this
analysis, the median survival was only 6.3 months. This poor
result may be due the comorbidities and poor PS of the
patients. There was a higher percentage of patients in the
chemonaive group who were male, had a nonadenocarcinoma
histology, and were smokers. These differences may further
explain the short median survival in these chemonaive patients.
Recently, mutations in the tyrosine kinase domain of
the EGFR gene were found to be associated with gefitinib
response in NSCLC patients.36–38 These mutations were de-
tected in about 10% of NSCLC patients who were white and
30% to 40% of patients who were Asian as a whole.37,39–45
EGFR tyrosine kinase mutations were predominantly seen in
female patients, patients who never smoked, those with ade-
TABLE 3. Association between Clinicopathologic Factors and Response to Gefitinib in 428 Patients
Total CR/PR SD/PD Univariate analysis pa Multivariate analysis pb
Gender 0.027 0.402
Male 237 53 (22.4%) 184 (77.6%)
Female 191 61 (31.9%) 130 (68.1%)
Performance status 0.001 0.001
0-1 170 63 (37.1%) 107 (62.9%)
2-4 258 51 (19.8%) 207 (80.2%)
Previous chemotherapy 0.015 0.001
No 142 49 (34.5%) 93 (65.5%)
Yes 286 65 (22.7%) 221 (77.3%)
Histology 0.004 0.008
Adenocarcinoma 319 96 (30.1%) 223 (69.9%)
Nonadenocarcinoma 109 18 (16.5%) 91 (83.5%)
Smoking history 0.012 0.294
Yes 215 46 (21.4%) 169 (78.6%)
No 213 68 (31.9%) 145 (68.1%)
CR/PR, complete response/partial response; SD/PD, stable disease/progressive disease. aFisher’s exact test bLogistic regression.
TABLE 4. Association between Clinicopathologic Factors
and Overall Survival in 428 Patients (Median Overall
Survival: 7.4 Months in All 428 Patients)
Median survival
(mo) (95% CI)
Univariate
analysis pa
Multivariate
analysis pb
Gender 0.008 0.459
Male 5.63 (3.91–7.36)
Female 9.37 (7.59–11.14)
Performance status 0.001 0.001
0–1 14.00 (10.70–17.30)
2–4 3.73 (2.74–4.73)
Prior chemotherapy 0.256
No 6.30 (3.80–8.80)
Yes 7.93 (6.01–9.86)
Histology 0.008 0.365
Adenocarcinoma 9.27 (7.52–11.01)
Nonadenocarcinoma 5.13 (3.78–6.48)
Smoking history 0.001 0.365
Yes 5.47 (4.05–6.88)
No 9.43 (7.47–11.40)
Response to gefitinib 0.001 0.001
CR/PR 15.73 (11.64–19.83)
SD/PD 4.37 (3.55–5.18)
CI, confidence interval; CR/PR, complete response/partial response; SD/PD, stable
disease/progressive disease. a Log-rank test. b Cox regression.
Journal of Thoracic Oncology • Volume 1, Number 6, July 2006 Predictive Factors of Gefitinib Antitumor Activity
Copyright © 2006 by the International Association for the Study of Lung Cancer 523
nocarcinoma histology, and patients of East Asian ethnic
origin. The status of EGFR tyrosine kinase mutation plays an
important role in predicting the response to gefitinib in East
Asian patients. However, not all responding patients harbor a
mutation in their tumors, which suggests that other markers
of sensitivity, such as EGFR and copy number, with growing
data43,46 may be needed for patient selection for gefitinib
treatment in the future.
Severe acute interstitial pneumonia occurred in Japan
after gefitinib use. Nearly 500 patients developed interstitial
pneumonia among 19,000 patients, and 124 died. Patients
with interstitial pneumonia also had other pulmonary disor-
ders such as previous thoracic irradiation, poor PS, and
pulmonary fibrosis.11,47 In this study, 12 of 428 patients
(2.8%) had acute interstitial pneumonia with gefitinib treat-
ment, and four of 12 patients died. The incidence was similar
to that in Japan and higher than in other places in the world.
In this analysis, painful paronychia with varying severity
occurred in 14.3% of the patients, much higher than what was
reported in the literature. Somatic gene polymorphism may
account for this side effect in East Asian populations and
should be explored in the future.
We conclude that gefitinib is very effective in the
treatment of advanced NSCLC in Taiwan. The independent
factors to select patients for gefitinib treatment are adenocar-
cinoma histology and good PS. However, in patients already
treated with chemotherapy, only good PS was an independent
factor to predict for tumor response and good survival.
Further well-controlled prospective studies in a more defined
population in this area are needed to confirm these findings.
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